公开(公告)号：WO2014169226A2

公开(公告)日：2014-10-16

申请号：PCT/US2014/033830

申请日：2014-04-11

申请人： PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY OF MEDICINE ,  DREXEL UNIVERSITY

发明人： AJIT, Seena ,  SACAN, Ahmet ,  ALEXANDER, Guillermo ,  SCHWARTZMAN, Robert, J. ,  MCDONALD, Marguerite

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  A61K31/135 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The invention includes compositions and methods useful for the diagnosis, prognosis, treatment, assessment, and characterization of inflammation or pain (e.g., neuropathic pain) in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with inflammation or pain. In one aspect, the invention relates to compositions and methods for the prediction of a subject's responsiveness of a treatment of inflammation or pain.

摘要翻译： 本发明包括可用于在有需要的受试者中诊断，预后，治疗，评估和表征炎症或疼痛（例如神经性疼痛）的组合物和方法，基于与至少一种miRNA相关的至少一种miRNA的表达水平 炎症或疼痛。 一方面，本发明涉及用于预测受试者对炎症或疼痛的治疗的反应性的组合物和方法。

公开(公告)号：WO2014089296A2

公开(公告)日：2014-06-12

申请号：PCT/US2013/073319

申请日：2013-12-05

申请人： INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH ,  PHILADELPHIA HEALTH & EDUCATION CORPORATION d/b/a DREXEL UNIVERSITY COLLEGE OF MEDICINE

发明人： XU, Xiaodong ,  BLOCK, Timothy, M. ,  GUO, Ju-Tao ,  DU, Yanming

IPC分类号： A61M31/00

CPC分类号： C07C233/66 ,  C07C233/75 ,  C07C235/64 ,  C07C2602/10 ,  C07D317/46 ,  C07D317/68 ,  C07D319/18 ,  C07D321/10 ,  C07D333/68 ,  C07D333/70 ,  C07D333/72 ,  C07D495/04

摘要： Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection.

摘要翻译： 本发明的药物组合物包含可用作治疗乙型肝炎病毒（HBV）感染的预先基因组RNA包封抑制剂的官能化苯甲酰胺衍生物。

公开(公告)号：WO2013055420A2

公开(公告)日：2013-04-18

申请号：PCT/US2012/046422

申请日：2012-07-12

申请人： PHILADELPHIA HEALTH & EDUCATION CORPORATION ,  INOVIO PHARMACEUTICALS, INC. ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  KUTZLER, Michele ,  BALIBAN, Scott ,  WEINER, David, B. ,  SARDESAI, Niranjan, Y. ,  KIM, J. Joseph

发明人： KUTZLER, Michele ,  BALIBAN, Scott ,  WEINER, David, B. ,  SARDESAI, Niranjan, Y. ,  KIM, J. Joseph

IPC分类号： A61K48/00 ,  A61K39/08

CPC分类号： A61K39/08 ,  A61K2039/53 ,  A61N1/327 ,  C07K14/33

摘要： The invention relates to compositions and methods for treating C. difficile associated disease (CD AD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.

摘要翻译： 本发明涉及通过向有需要的受试者施用编码毒素A和毒素B中的至少一种的至少一部分的至少一种核酸来治疗艰难梭菌相关疾病（CDAD）的组合物和方法。

公开(公告)号：WO2012078752A3

公开(公告)日：2012-06-14

申请号：PCT/US2011/063735

申请日：2011-12-07

申请人： PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE ,  LU, Xuanyong ,  BLOCK, Timothy, M.

发明人： LU, Xuanyong ,  BLOCK, Timothy, M.

IPC分类号： C07K16/08 ,  G01N33/53

摘要： An anti-SPIK antibody specific for an epitope comprising the first nine amino acids of intact SPIK is disclosed. Further, a diagnostic kit is provided comprising at least one antibody specific for an epitope comprising the first nine amino acids of intact SPIK to diagnose patients exhibiting disease symptoms or at risk for developing a disease, wherein the disease is HBV infection, HCV infection, hepatitis, cancer or hepatic cancer.

公开(公告)号：WO2010107741A1

公开(公告)日：2010-09-23

申请号：PCT/US2010/027404

申请日：2010-03-16

申请人： DREXEL UNIVERSITY ,  PHILADELPHIA HEALTH & EDUCATION CORPORATION ,  FRIDMAN, Gregory ,  DOBRYNIN, Danil, V. ,  FRIDMAN, Alexander ,  FRIEDMAN, Gennady ,  CHAKRAVARTHY, Kalyan ,  MURTHY, Sreekant

发明人： FRIDMAN, Gregory ,  DOBRYNIN, Danil, V. ,  FRIDMAN, Alexander ,  FRIEDMAN, Gennady ,  CHAKRAVARTHY, Kalyan ,  MURTHY, Sreekant

IPC分类号： A61N1/00

CPC分类号： A61N1/40 ,  H05H1/24 ,  H05H1/2406 ,  H05H2001/2412 ,  H05H2001/245 ,  H05H2240/20 ,  H05H2245/122

摘要： Non-thermal plasma is a partly ionized gas, which can be generated by a high-voltage electric field at a low pressure. Disclosed herein are apparatuses and methods for treating an enteric disease in vivo using non-thermal plasma. The disclosed apparatuses have a first conduit comprising a lumen and a tip; a first electrode disposed within the lumen of the first conduit; a second electrode comprised of a metal conduit disposed within the first conduit; an insulator disposed within the lumen of the first conduit, the insulator configured to electrically insulate the first electrode from the second electrode; and a gas channel disposed between the outer surface of the metal conduit and the inner surface of the first conduit, the gas channel being capable of feeding a gas from a gas source to the tip, wherein when the potential is applied, the gas is ionized to produce the non-thermal plasma.

摘要翻译： 非热等离子体是部分电离的气体，其可以通过在低压下的高压电场产生。 本文公开了使用非热等离子体在体内治疗肠道疾病的装置和方法。 所公开的装置具有包括内腔和尖端的第一导管; 设置在所述第一导管的内腔内的第一电极; 第二电极，包括设置在第一导管内的金属导管; 设置在所述第一导管的内腔内的绝缘体，所述绝缘体被配置为使所述第一电极与所述第二电极电绝缘; 以及设置在金属导管的外表面和第一导管的内表面之间的气体通道，气体通道能够将气体从气体源供给到尖端，其中当施加电位时，气体被电离 以产生非热等离子体。

公开(公告)号：WO2010059832A1

公开(公告)日：2010-05-27

申请号：PCT/US2009/065156

申请日：2009-11-19

申请人： DREXEL UNIVERSITY ,  PHILADELPHIA HEALTH & EDUCATION CORPORATION d/b/a DREXEL UNIVERSITY COLLEGE OF MEDICINE ,  GISZTER, Simon ,  KIM, Tae, Gyo ,  RAMAKRISHNAN, Arun

发明人： GISZTER, Simon ,  KIM, Tae, Gyo ,  RAMAKRISHNAN, Arun

IPC分类号： D04C3/00

CPC分类号： D04C3/42

摘要： A method and apparatus for fabricating microbraided structures is provided. A microbraiding device includes first and second carrier members that are movable with respect to each other. Each carrier includes a plurality of shelters. Spool-less strands of microfiber are retained in shuttles that are movable between the first and second shelters under magnetic forces. The microbraid structure is fabricated as the shuttles move between the first shelters, and as the first carrier member moves relative to the second carrier member.

摘要翻译： 提供了一种用于制造微阵列结构的方法和装置。 微型装置包括可相对于彼此移动的第一和第二承载构件。 每个载体包括多个收容所。 无纺布的超细纤维束被保留在可在磁力下在第一和第二收容所之间移动的梭子中。 随着梭子在第一遮蔽物之间移动，并且当第一承载构件相对于第二承载构件移动时，制作微框架结构。

公开(公告)号：WO2008094922A1

公开(公告)日：2008-08-07

申请号：PCT/US2008/052331

申请日：2008-01-29

申请人： PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE ,  ELLIS-DAVIES, Graham

发明人： ELLIS-DAVIES, Graham

IPC分类号： C07F9/572 ,  C07F9/00 ,  C07D209/04 ,  A61K31/404

CPC分类号： C07F9/5728 ,  C07D209/08

摘要： The present invention relates to photolabile or photoreleasable compounds including a caging moiety linked to an effector moiety, wherein the compounds are capable of releasing the effector moiety on irradiation, typically by flash irradiation with UV light. These compounds are particularly suitable for focal 2-photon uncaging The photoreleasable compounds can be used to deliver effector moieties such as carboxylic acids, preferably, neuroactive amino acids to sites where their activity is required. In preferred embodiments of the invention, the caging moiety is based on 4-carboxymethoxy-5,7-dinitroinlinyl and derivatives thereof.

摘要翻译： 本发明涉及光不稳定或光可释放化合物，其包括与效应子部分连接的笼状部分，其中所述化合物通常通过紫外线的闪光照射在照射时释放效应部分。 这些化合物特别适用于焦点2光子褪色。可光致发光的化合物可用于将效应部分如羧酸，优选神经活性氨基酸递送至需要其活性的位点。 在本发明的优选实施方案中，笼状部分基于4-羧基甲氧基-5,7-二硝基苯乙烯基及其衍生物。

公开(公告)号：WO2014059248A1

公开(公告)日：2014-04-17

申请号：PCT/US2013/064503

申请日：2013-10-11

申请人： PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A/ DREXEL ,  THE BABRAHAM INSTITUTE

发明人： KATSIKIS, Peter, D. ,  GRACIAS, Donald, T. ,  TURNER, Martin

IPC分类号： C12N5/071 ,  C12N15/00 ,  A61K48/00

CPC分类号： C12N15/113 ,  A61K35/17 ,  C12N5/0636 ,  C12N2310/141 ,  C12N2501/65

摘要： The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as "CD8+ T cell immunity") in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells.

摘要翻译： 本发明提供了具有疾病状态的患者中增强CD8 + T细胞介导的免疫（也称为“CD8 + T细胞免疫”）的新方法。 特别地，本发明通过引入编码miR-155转录物的核酸分子或编码嵌合抗原受体和miR的核酸分子来提供miR-155在患者特异性T细胞群体中的增强表达 -155转录到这些细胞中，随后将T细胞重新引入患者体内。 本发明还提供了相对于对照细胞增强这些T细胞的扩增的方法。 增强的miR-155表达后CD8 + T细胞的增加与增强的CD8 + T细胞免疫直接相关。 本发明还提供了通过增加miR-155在患者特异性T细胞中的表达来增强患者抗癌免疫的方法。

公开(公告)号：WO2014015157A2

公开(公告)日：2014-01-23

申请号：PCT/US2013/051110

申请日：2013-07-18

申请人： PHILADELPHIA HEALTH & EDUCATION CORPORATION

发明人： KIM, Felix J. ,  SALVINO, Joseph M.

IPC分类号： A61K31/155

CPC分类号： A61K31/155 ,  A61K9/06 ,  A61K9/7023 ,  A61K31/138 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/69 ,  A61K45/06 ,  C07C279/18 ,  C07D209/48 ,  C07D311/16 ,  A61K2300/00

摘要： The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.

摘要翻译： 本发明包括可用于预防，治疗或改善Sigma相关疾病或疾病的化合物。 本发明的化合物可以调节细胞蛋白质体内平衡，其包括蛋白质的翻译起始，折叠，加工，转运和降解（包括遍在蛋白选择性自噬）。 本发明还包括在有需要的受试者中预防，治疗或改善与Sigma相关的病症或疾病的方法，所述方法包括向受试者施用有效量的Sigma-调节化合物。 本发明还包括在有需要的受试者中预防，治疗或改善与Sigma相关的病症或疾病的方法，所述方法包括向所述受试者施用有效量的Sigma-调节化合物，所述方法还包括给予有效量的 一种抑制泛素蛋白酶体系统（UPS）和/或自噬存活途径的化合物。

公开(公告)号：WO2012048033A3

公开(公告)日：2012-04-12

申请号：PCT/US2011/054969

申请日：2011-10-05

申请人： DREXEL UNIVERSITY ,  PHILADELPHIA HEALTH & EDUCATION CORPORATION ,  CHAIKEN, Irwin ,  PAPAZOGLOU, Elisabeth ,  BASTIAN, Arangassery, Rosemary ,  KANTHARAJU

发明人： CHAIKEN, Irwin ,  PAPAZOGLOU, Elisabeth ,  BASTIAN, Arangassery, Rosemary ,  KANTHARAJU

IPC分类号： A61K38/10 ,  A61K38/00

摘要： The present invention includes a composition comprising a gold nanoparticle compiexed with a cysteine-containing compound. The invention also includes the method of preparing a composition comprising a gold nanoparticle compiexed with a cysteine-containing compound. The invention ftirther includes a method of causing virolysis of a virus using the compositions described therein. The invention ftirther includes a method of inhibiting vims entry using the compositions described therein.